title: Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression.
abstract: BACKGROUND
  Atypical depression is associated with elevated rates of personality disorders. Studies have confirmed the efficacy of a several antidepressants in the treatment of atypical depression. Whether their pathological dimensions of personality diminish after benefitting from effective medication treatment is unclear.
  
  
  OBJECTIVE
  To determine the extent that pathological dimensions of character improved among patients who benefitted from treatment.
  
  
  METHODS
  One-hundred and fifty-four outpatients with DSM-IV Major Depression who met Columbia criteria for atypical depression were randomized to receive fluoxetine, imipramine or placebo for a 10-week double-blind clinical trial. The Temperament and Character Inventory (TCI) was administered at the initiation of treatment and 8 weeks later. Low scores on either of two Character dimensions (Self-Directiveness or Cooperativeness) indicate psychopathology.
  
  
  RESULTS
  Responders had a substantial reduction in Harm Avoidance, but post-treatment scores remained significantly higher than the normal control group (NCG). Fluoxetine and Imipramine did not produce different changes on personality, except for Self-Transcendence.
  
  
  CONCLUSIONS
  High proportion of missing data, inadequate sample size, post-hoc analysis.
  
  
  CONCLUSIONS
  Among responders, Self-Directiveness improved and normalized; Harm Avoidance also improved but did not normalize. These data suggests that effective treatments reduce some pathological personality traits as well as improving mood.
authors.affiliation: New York State Psychiatric Institute, Unit 35, 1051 Riverside Drive, New York, NY 10032, USA. agostiv@pi.cpmc.columbia.edu
authors.forename: Vito
authors.initials: V
authors.lastname: Agosti
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: McGrath
mesh_terms: D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D002648:Child; D003866:Depressive Disorder / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010554:Personality Disorders / Q000209:etiology*; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D010919:Placebos; D005473:Fluoxetine